Literature DB >> 21587226

Prostate cancer: targeted therapy for prostate cancer metastases to bone.

Robert Coleman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21587226     DOI： 10.1038/nrurol.2011.63

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

Authors:  Henry G Bone; Michael A Bolognese; Chui Kin Yuen; David L Kendler; Paul D Miller; Yu-Ching Yang; Luanda Grazette; Javier San Martin; J Christopher Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

4.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Authors:  Janet E Brown; Richard J Cook; Pierre Major; Allan Lipton; Fred Saad; Matthew Smith; Ker-Ai Lee; Ming Zheng; Yong-Jiang Hei; Robert E Coleman
Journal:  J Natl Cancer Inst       Date:  2005-01-05       Impact factor: 13.506

5.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Authors:  Robert E Coleman; Pierre Major; Allan Lipton; Janet E Brown; Ker-Ai Lee; Matthew Smith; Fred Saad; Ming Zheng; Yong Jiang Hei; John Seaman; Richard Cook
Journal:  J Clin Oncol       Date:  2005-06-27       Impact factor: 44.544

6.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

7.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Authors:  Karim Fizazi; Allan Lipton; Xavier Mariette; Jean-Jacques Body; Yasmin Rahim; Julie R Gralow; Guozhi Gao; Ling Wu; Winnie Sohn; Susie Jun
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

8.  Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

Authors:  Allan Lipton; Guenther G Steger; Jazmin Figueroa; Cristina Alvarado; Philippe Solal-Celigny; Jean-Jacques Body; Richard de Boer; Rossana Berardi; Pere Gascon; Katia S Tonkin; Robert Coleman; Alexander H G Paterson; Mark C Peterson; Michelle Fan; Amy Kinsey; Susie Jun
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

9.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.